Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study)

BACKGROUND: Dacomitinib is the first second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to significantly improve overall survival in the patients of EGFR mutation-positive inoperable or postoperative recurrent non-small cell lung cancer (NSCLC). However, dermatol...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Transl Lung Cancer Res
Auteurs principaux: Iwasaku, Masahiro, Uchino, Junji, Yamada, Tadaaki, Chihara, Yusuke, Shimamoto, Takayuki, Tamiya, Nobuyo, Kaneko, Yoshiko, Kiyomi, Fumiaki, Takayama, Koichi
Format: Artigo
Langue:Inglês
Publié: AME Publishing Company 2019
Sujets:
Study Protocol
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6749124/
https://ncbi.nlm.nih.gov/pubmed/31555524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2019.08.03
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires